After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

I’m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’m wondering about Ozempic.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

With GLP-1 weight loss comes muscle loss. Gyms and personal trainers are rising to the challenge to help people build it back ...

I’m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’m wondering about Ozempic. How does that work? I’m ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...